SECsense Logo

Xeris Biopharma Holdings, Inc. 8-K Report: Key Updates for Investors (Jan 2025)

$XERS
Form 8-K
Filed on: 2025-01-10
Source
Xeris Biopharma Holdings, Inc. 8-K Report: Key Updates for Investors (Jan 2025)

Here’s a summary of the key information extracted from the provided section of the financial report:

  1. Company Information:
  • Name: Xeris Biopharma Holdings, Inc.
  • State of Incorporation: Delaware (DE)
  • CIK Number: 0001867096
  • Address: 1375 West Fulton Street, Suite 1300, Chicago, IL 60607
  • Contact Number: 844 445-5704
  1. Filing Details:
  • Filing Type: 8-K (Current Report)
  • Filing Date: January 10, 2025
  • Period Covered: January 10, 2025
  1. Financial Information:
  • Security Type: Common Stock
  • Par Value: $0.0001 per share
  • Ticker Symbol: XERS
  • Exchange: NASDAQ
  1. Additional Context:
  • The filing is part of the company's ongoing disclosure obligations, typically used to announce significant events that shareholders should know about.

This report primarily serves to inform stakeholders about recent developments pertaining to Xeris Biopharma Holdings, Inc. It is important for investors and analysts to monitor such filings for any material events that could impact the company's stock performance or operational outlook.